Skip to main content
TipRanks
Go Ultimate75% OFF

EBOS Group Limited (EBO) AI Stock Analysis

6 Followers
NZ:EBO

EBOS Group Limited

(NZX:EBO)

Select Model
Rating:60Neutral
Price Target:NZD 23.00â–²(5.84% Upside)
Action:initiatedcoverage
Date:10/05/26

The score is held back primarily by weaker financial consistency (FY2026 revenue and margin deterioration) and bearish technical momentum (downtrend across key moving averages, negative MACD). Offsetting factors include a supportive valuation profile (moderate P/E and high dividend yield) and a solid earnings-call outlook with FY27 EBITDA growth guidance and improving free-cash-flow expectations from lower CapEx, despite acknowledged headwinds.

Positive Factors
Diversified healthcare and animal-care growthGrowth across Animal Care, Healthcare and Contract Logistics demonstrates a broad earnings base rather than reliance on one product category. This diversification, supported by customer wins and expanding premium offerings, can improve resilience and sustain revenue opportunities over the next several quarters.
Negative Factors
Revenue and margin volatilityThe sharp FY26 revenue contraction and material gross-margin compression reduce confidence that recent earnings performance is consistently repeatable. Even if some distortion was temporary, weaker operating visibility can constrain reinvestment capacity and make future profit growth more dependent on recovery conditions.

EBOS Group Limited (EBO) vs. SPDR S&P 500 ETF (SPY)

-40%-30%-20%-10%0%10%20%NZ:EBO-19.15%SPY+8.20%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
NZD 3.74B
Dividend Yield
5.67%
Average Volume (3M)
186.56K
Price to Earnings (P/E)
16.7
Beta (1Y)
0.90
Revenue Growth
16.36%
EPS Growth
5.52%
Country
NZ
Employees
5,364
Sector
Healthcare
Sector Strength
51
Industry
Medical - Distribution

EBOS Group Limited Business Overview & Revenue Model

Company Description

EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. It operates through Healthcare and Animal Care segments. The comp...

How the Company Makes Money

EBOS primarily makes money by acting as a large-scale wholesaler and distributor between manufacturers (pharmaceutical, medical device/consumables, and animal health suppliers) and end customers (notably community pharmacies, hospitals, healthcare pr...

EBOS Group Limited Earnings Call Summary

Earnings Call Date:Aug 18, 2026(Q4-2026)|% Change Since:2.65%|Next Earnings Date:Feb 23, 2027
Earnings Call SentimentPositive

The call communicated solid top‑line growth, completion of a major A$360m infrastructure program that materially reduces future capital needs, meaningful momentum in higher-growth divisions (Animal Care, Medical Technology, Retail Pharmacy Brands) and a disciplined M&A and capital allocation approach. Temporary headwinds were acknowledged — notably FX translation, fuel costs, margin pressure and a known NZ contract roll-off — but management framed these as manageable or transitory and backed guidance that excludes further acquisitions. Balance sheet metrics, free cash flow generation and a maintained dividend were highlighted as strengths. Overall the positives (portfolio re‑positioning, completed investment cycle, strong divisional growth and capital flexibility) outweigh the measurable but contained lowlights.

Positive Updates

Revenue and Underlying EBITDA Growth
Group revenue rose 9.9% to A$13.5bn and underlying EBITDA increased 5% to A$614m; underlying NPAT was A$250m. On a statutory basis EBITDA was up 7.8% and NPAT up 4.7%.

Negative Updates

Fuel and Foreign Exchange Headwinds
Management cited approximately A$22m of combined fuel and FX headwinds in FY'26 (fuel impact around A$5m). A stronger Australian dollar — a 13‑year high vs the NZD — materially affected translated earnings and purchasing costs (notably in Medical Technology).

Company Guidance

EBOS guided FY27 underlying EBITDA of A$635–655 million (midpoint ~A$645m), implying mid‑single‑digit EBITDA growth and explicitly excluding any new acquisitions; CapEx is expected to normalise to ~A$100m (down from A$145m in FY26), supporting stronger free cash flow after FY26 reported free cash flow of A$204m and facilitating ~A$150m of additional bolt‑on M&A capacity within a leverage ceiling of 2.3x (FY26 leverage 2.1x, target range 1.7–2.3x) and with A$726m undrawn committed facilities and WA debt maturity >3 years. Management also flagged a targeted 30% productivity uplift at Kemps Creek by end FY27, stable cash conversion days (~20) and only A$7m NWC growth on 10% revenue growth, while noting depreciation and financing costs will be elevated as recent investments are annualised and the final dividend was maintained at A$0.615 per share.

EBOS Group Limited Financial Statement Overview

Summary

Financials look generally stable but are clouded by FY2026 volatility: a sharp revenue contraction and notable margin compression reduce confidence in earnings quality. Offsetting this, leverage appears manageable and free cash flow remains positive, indicating underlying resilience.

Income Statement

58Neutral

Balance Sheet

64Positive

Cash Flow

62Positive
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue13.17B12.84B12.20B13.15B12.25B10.77B
Gross Profit933.71M910.40M1.63B1.63B1.56B1.25B
EBITDA544.98M531.22M535.23M593.97M575.21M401.44M
Net Income219.64M214.33M213.89M270.67M253.57M203.26M
Balance Sheet
Total Assets7.83B7.83B7.24B6.72B6.44B6.28B
Cash, Cash Equivalents and Short-Term Investments239.29M239.29M183.19M249.74M212.05M518.99M
Total Debt1.90B1.90B1.61B1.64B1.28B1.65B
Total Liabilities5.12B5.12B4.53B4.31B4.14B4.13B
Stockholders Equity2.75B2.75B2.72B2.45B2.44B2.27B
Cash Flow
Free Cash Flow213.26M207.07M365.99M262.89M293.26M159.62M
Operating Cash Flow345.31M332.10M416.08M347.11M391.68M249.54M
Investing Cash Flow-274.43M-258.79M-366.72M-376.90M-154.39M-1.40B
Financing Cash Flow-4.03M-11.74M-84.41M34.22M-547.56M1.51B

EBOS Group Limited Technical Analysis

Technical Analysis SentimentPositive
Last Price21.73

Price Trends

50DMA20.31Positive
100DMA20.78Positive
200DMA20.99Positive

Market Momentum

MACD0.45Negative
RSI57.30Neutral
STOCH60.27Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NZ:EBO, the sentiment is Positive. The current price of 21.73 is above the 20-day moving average (MA) of 21.26, above the 50-day MA of 20.31, and above the 200-day MA of 20.99, indicating a bullish trend. The MACD of 0.45 indicates Negative momentum. The RSI at 57.30 is Neutral, neither overbought nor oversold. The STOCH value of 60.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NZ:EBO.

EBOS Group Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

NZ:EBO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
NZ:FPHNZ:FPH80OutperformNZD 29.03B61.6522.84%1.24%15.59%23.94%
NZ:EBONZ:EBO60NeutralNZD 4.54B16.737.99%5.67%16.36%5.52%
NZ:RYMNZ:RYM56NeutralNZD 1.91B-11.19-4.17%―11.86%72.99%
NZ:AFTNZ:AFT54NeutralNZD 485.57M32.3914.07%0.64%22.44%23.14%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
NZ:PEBNZ:PEB45NeutralNZD 341.52M-6.92-190.54%―-47.36%-3.79%
NZ:TRUNZ:TRU37UnderperformNZD 8.38M-2.58-75.57%―42.20%23.68%

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%NZ:EBONZ:FPHNZ:PEBNZ:RYMNZ:TRUNZ:AFTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
NZ:EBO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
NZ:EBOEBOS Group Limited21.73-5.67-20.68%
NZ:FPHFisher & Paykel Healthcare Corporation Limited49.3512.6334.41%
NZ:PEBPacific Edge Limited0.280.0951.93%
NZ:RYMRyman Healthcare 1.88-1.01-34.93%
NZ:TRUTruScreen Group Ltd.0.01-0.01-41.18%
NZ:AFTAFT Pharmaceuticals Ltd.4.630.9726.47%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 05, 2026